ICU Medical stock
ICUINASDAQICU Medical, Inc., HealthcareISIN US44930G1076
53Score 53 out of 100, Neutral
Price and trend
87 / 100
Price history
+27% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 5.3% below its 52-week high. Largest decline in 20 years: 74% (June 2018 to November 2023).
Chart figures for advanced users
- SMA 50$163.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$149.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$115.45
- The lowest closing price of the last twelve months.
- Resistance$187.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ICU Medical, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $4.43B, is number 23 of 44 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $2.19B (down 1.9%) and adjusted earnings per share of $8.74 (up 12.6%).
- MEQIRI Score 53 out of 100 (Neutral): rank 353 of 702 in Healthcare, median 53.
Show more
- The P/E is 73.9 (Medical (Instruments & Supplies) median 34.6, own median of recent years 50.2).
- Our model puts fair value at $120.66, with the price 47% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 346% of earnings over the last 12 months.Fundamentals 63
Weaknesses
- Earnings per share fallingDown 62.8% a year since 2020.Growth 47
- Interest barely coveredOperating profit covers interest only 1 times.Stability 59
- Richly valuedP/E 73.9, Medical (Instruments & Supplies) median 34.6, own median 50.2.Valuation 23
Its standout strengths are technical analysis and momentum, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 54 to 53.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $92.81 and expensive above $172.37 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $158.42 (cash-flow model) and $82.90 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $106.87, at 7.8% it would be $141.38.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 5.9% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 37%, operating 5%, net 0%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 5 Nov 2026EPS reported $2.44 (expected $2.14)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $8.740.0%
- Revenue
- $2.19B0.0%
- Earnings per share
- $9.670.0%
- Revenue
- $2.28B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +10.9%Guidance raised: adjusted EBITDA of $415 million to $435 million (previously $400 million to $430 million) and adjusted EPS of $8.60 to $9.00 (previously $7.75 to $8.45).
“For full year adjusted EBITDA, we are raising and narrowing our previous guidance range of $400 million to $430 million to a range of $415 million to $435 million. And for full year adjusted EPS, we are raising and narrowing our previous guidance range of $7.75 to $8.45 per share to $8.60 to $9 per share.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $7.21M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sanzone Virginia RuthSale
3 Sept 2026, VP, General Counsel
- Shares
- 4,856
- Price
- $168.69
- Value
- $819,150
- Bonnell Brian MichaelSale
1 Sept 2026, Chief Financial Officer
- Shares
- 6,381
- Price
- $175.00
- Value
- $1.12M
- Bonnell Brian MichaelSale
31 Aug 2026, Chief Financial Officer
- Shares
- 9,307
- Price
- $172.79
- Value
- $1.61M
Show 6 more
- Woolson DanielSale
13 Aug 2026, VP, GM-Infusion Capital
- Shares
- 5,417
- Price
- $181.33
- Value
- $982,265
- Sousa BenSale
12 Aug 2026, Chief Information Officer
- Shares
- 2,250
- Price
- $178.32
- Value
- $401,209
- Voigtlander Christian B.Sale
11 Aug 2026, Chief Operating Officer
- Shares
- 8,929
- Price
- $182.93
- Value
- $1.63M
- Finney Elisha WSale
11 Aug 2026, Board
- Shares
- 378
- Price
- $182.48
- Value
- $68,978
- Woolson DanielSale
22 May 2026, President
- Shares
- 2,123
- Price
- $132.21
- Value
- $280,685
- Sanzone Virginia RuthSale
14 May 2026, VP, General Counsel
- Shares
- 2,447
- Price
- $124.08
- Value
- $303,624
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at ICU Medical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Asahi Intecc7747.T $6.42B83
- Gan & Lee Pharmaceuticals.603087.SS $6.15B55
- TeleflexTFX $6.07B59
- Merit Medical SystemsMMSI $5.19B61
- Envista HoldingsNVST $3.95B71
- Stevanato GroupSTVN $3.92B49
- Tecan GroupTECN.SW $3.9B52
- Pulse BiosciencesPLSE $3.84B46
ETFs that hold ICU Medical
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.25% | 0.30% | €2.31B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.15% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.15% | 0.30% | €2.22B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.14% | 0.30% | €185.82M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.13% | 0.10% | €395.74M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.10% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €964.08M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.04% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.